EMEA-001032-PIP01-10-M04

Key facts

Invented name
Opsumit
Active substance
Macitentan
Therapeutic area
Cardiovascular diseases
Decision number
P/0480/2021
PIP number
EMEA-001032-PIP01-10-M04
Pharmaceutical form(s)
  • Dispersible tablet
  • Film-coated tablet
Condition(s) / indication(s)
  • Treatment of idiopathic pulmonary fibrosis
  • Treatment of pulmonary arterial hypertension
  • Treatment of systemic sclerosis
Route(s) of administration
Oral use
Contact for public enquiries
Janssen-Cilag International NV

Email: clinical-trials-disclosure@actelion.com
Tel. +41 615656565
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating